Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Inflammatory lung disorders (ILDs) are one of the world’s major reasons for fatalities and sickness, impacting millions of individuals of all ages and constituting a severe and pervasive health hazard. Asthma, lung cancer, bronchiectasis, pulmonary fibrosis acute respiratory distress syndrome, and COPD all include inflammation as a significant component. Microbe invasions, as well as the damage and even death of host cells, can cause and sustain inflammation. To counteract the negative consequences of irritants, the airways are equipped with cellular and host defense immunological systems that block the cellular entrance of these irritants or eliminate them from airway regions by triggering the immune system. Failure to activate the host defense system will trigger chronic inflammatory cataracts, leading to permanent lung damage. This damage makes the lungs more susceptible to various respiratory diseases. There are certain restrictions of the available therapy for lung illnesses. Vitamins are nutritional molecules that are required for optimal health but are not produced by the human body. Cholecalciferol (Vitamin D) is classified as a vitamin, although it is a hormone. Vitamin D is thought to perform a function in bone and calcium homeostasis. Recent research has found that vitamin D can perform a variety of cellular processes, including cellular proliferation; differentiation; wound repair; healing; and regulatory systems, such as the immune response, immunological, and inflammation. The actions of vitamin D on inflammatory cells are dissected in this review, as well as their clinical significance in respiratory illnesses.

Details

Title
Current Overview on Therapeutic Potential of Vitamin D in Inflammatory Lung Diseases
Author
Afzal, Muhammad 1   VIAFID ORCID Logo  ; Kazmi, Imran 2   VIAFID ORCID Logo  ; Al-Abbasi, Fahad A 2 ; Alshehri, Sultan 3   VIAFID ORCID Logo  ; Ghoneim, Mohammed M 4   VIAFID ORCID Logo  ; Imam, Syed Sarim 3   VIAFID ORCID Logo  ; Muhammad Shahid Nadeem 2   VIAFID ORCID Logo  ; Maryam Hassan Al-Zahrani 2 ; Alzarea, Sami I 1   VIAFID ORCID Logo  ; Alquraini, Ali 5   VIAFID ORCID Logo 

 Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka 72341, Saudi Arabia; [email protected] (M.A.); [email protected] (S.I.A.) 
 Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia; [email protected] (F.A.A.-A.); [email protected] (M.S.N.); [email protected] (M.H.A.-Z.) 
 Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; [email protected] (S.A.); [email protected] (S.S.I.) 
 Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia; [email protected] 
 Department of Pharmaceutical Chemistry, Faculty of Clinical Pharmacy, Al Baha University, Al Baha 65779, Saudi Arabia; [email protected] 
First page
1843
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
22279059
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2612752403
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.